Springer Seminars in Immunopathology

, Volume 28, Issue 3, pp 239–253 | Cite as

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector

  • David K. Clarke
  • David Cooper
  • Michael A. Egan
  • R. Michael Hendry
  • Christopher L. Parks
  • Stephen A. Udem
Review

Abstract

Recombinant vesicular stomatitis virus (rVSV) is currently under evaluation as a human immunodeficiency virus (HIV)-1 vaccine vector. The most compelling reasons to develop rVSV as a vaccine vector include a very low seroprevalence in humans, the ability to infect and robustly express foreign antigens in a broad range of cells, and vigorous growth in continuous cell lines used for vaccine manufacture. Numerous preclinical studies with rVSV vectors expressing antigens from a variety of human pathogens have demonstrated the versatility, flexibility, and potential efficacy of the rVSV vaccine platform. When administered to nonhuman primates (NHPs), rVSV vectors expressing HIV-1 Gag and Env elicited robust HIV-1-specific cellular and humoral immune responses, and animals immunized with rVSV vectors expressing simian immunodeficiency virus (SIV) Gag and HIV Env were protected from AIDS after challenge with a pathogenic SIV/HIV recombinant. However, results from an exploratory neurovirulence study in NHPs indicated that these prototypic rVSV vectors might not be adequately attenuated for widespread use in human populations. To address this safety concern, a variety of different attenuation strategies, designed to produce a range of further attenuated rVSV vectors, are currently under investigation. Additional modifications of further attenuated rVSV vectors to upregulate expression of HIV-1 antigens and coexpress molecular adjuvants are also being developed in an effort to balance immunogenicity and attenuation.

Keywords

VSV Immunogenicity Neurovirulence Safety AIDS 

Notes

Acknowledgements

This work was sponsored by a HIV-1 Vaccine Design and Development Team contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases (HVDDT NO1-A1-25458).

References

  1. 1.
    Abraham G, Banerjee AK (1976) Sequential transcription of the genes of vesicular stomatitis virus. Proc Natl Acad Sci USA 73:1504PubMedGoogle Scholar
  2. 2.
    Ahmed M, McKenzie MO, Puckett S et al (2003) Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77:4646PubMedGoogle Scholar
  3. 3.
    Arnheiter H, Davis NL, Wertz G et al (1985) Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis. Cell 41:259PubMedGoogle Scholar
  4. 4.
    Ball LA, White CN (1976) Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci USA 73:442PubMedGoogle Scholar
  5. 5.
    Ball LA, Pringle CR, Flanagan B et al (1999) Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73:4705PubMedGoogle Scholar
  6. 6.
    Bergold GH, Suarez OM, Munz K (1968) Multiplication in and transmission by Aedes aegypti of vesicular stomatitis virus.J Invertebr Pathol 11:406PubMedGoogle Scholar
  7. 7.
    Bhatt PN, Rodrigues FM (1967) Chandipura: a new Arbovirus isolated in India from patients with febrile illness. Indian J Med Res 55:1295PubMedGoogle Scholar
  8. 8.
    Black BL, Lyles DS (1992) Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol 66:4058PubMedGoogle Scholar
  9. 9.
    Blumberg BM, Leppert M, Kolakofsky D (1981) Interaction of VSV leader RNA and nucleocapsid protein may control VSV genome replication. Cell 23:837PubMedGoogle Scholar
  10. 10.
    Blumberg BM, Giorgi C, Kolakofsky D (1983) N protein of vesicular stomatitis virus selectively encapsidates leader RNA in vitro. Cell 32:559PubMedGoogle Scholar
  11. 11.
    Buonocore L, Blight KJ, Rice CM et al (2002) Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 76:6865PubMedGoogle Scholar
  12. 12.
    Calisher CH, Monath TP, Sabattini MS et al (1987) A newly recognized vesiculovirus, Calchaqui virus, and subtypes of Melao and Maguari viruses from Argentina, with serologic evidence for infections of humans and horses. Am J Trop Med Hyg 36:114PubMedGoogle Scholar
  13. 13.
    Carroll AR, Wagner RR (1979) Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol 29:134PubMedGoogle Scholar
  14. 14.
    Casimiro DR, Chen L, Fu TM et al (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.J Virol 77:6305PubMedGoogle Scholar
  15. 15.
    Clinton GM, Little SP, Hagen FS et al (1978) The matrix (M) protein of vesicular stomatitis virus regulates transcription. Cell 15:1455PubMedGoogle Scholar
  16. 16.
    Das T, Pattnaik AK, Takacs AM et al (1997) Basic amino acid residues at the carboxy-terminal eleven amino acid region of the phosphoprotein (P) are required for transcription but not for replication of vesicular stomatitis virus genome RNA. Virology 238:103PubMedGoogle Scholar
  17. 17.
    Dhanda V, Rodrigues FM, Ghosh SN (1970) Isolation of Chandipura virus from sandflies in Aurangabad. Indian J Med Res 58:179PubMedGoogle Scholar
  18. 18.
    Domingo E, Holland JJ (1997) RNA virus mutations and fitness for survival. Annu Rev Microbiol 51:151PubMedGoogle Scholar
  19. 19.
    Egan MA, Chong SY, Rose NF et al (2004) Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20:989PubMedGoogle Scholar
  20. 20.
    Egan MA, Chong SY, Megati S et al (2005) Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 21:629PubMedGoogle Scholar
  21. 21.
    Emerson SU, Yu Y (1975) Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus. J Virol 15:1348PubMedGoogle Scholar
  22. 22.
    Ezelle HJ, Markovic D, Barber GN (2002) Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol 76:12325PubMedGoogle Scholar
  23. 23.
    Faria PA, Chakraborty P, Levay A et al (2005) VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 17:93PubMedGoogle Scholar
  24. 24.
    Fields BN, Hawkins K (1967) Human infection with the virus of vesicular stomatitis during an epizootic. New Engl J Med 277:989PubMedCrossRefGoogle Scholar
  25. 25.
    Finke S, Conzelmann KK (2005) Recombinant rhabdoviruses: vectors for vaccine development and gene therapy. Curr Top Microbiol Immunol 292:165PubMedGoogle Scholar
  26. 26.
    Flamand A (1970) Genetic study of vesicular stomatitis virus: classification of spontaneous thermosensitive mutants into complementation groups (in French). J Gen Virol 8:187PubMedGoogle Scholar
  27. 27.
    Flanagan EB, Zamparo JM, Ball LA et al (2001) Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75:6107PubMedGoogle Scholar
  28. 28.
    Flanagan EB, Schoeb TR, Wertz GW (2003) Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice. J Virol 77:5740PubMedGoogle Scholar
  29. 29.
    Frank AH, Appleby A, Seibold HR (1945) Experimental intracerebral infection of horses, cattle, and sheep with the virus of vesicular stomatitis. Am J Vet Res 28Google Scholar
  30. 30.
    Fredericksen BL, Whitt MA (1998) Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness. Virology 240:349PubMedGoogle Scholar
  31. 31.
    Fukushi S, Mizutani T, Saijo M et al (2005) Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 86:2269PubMedGoogle Scholar
  32. 32.
    Garbutt M, Liebscher R, Wahl-Jensen V et al (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78:5458PubMedGoogle Scholar
  33. 33.
    Geisbert TW, Jones S, Fritz EA et al (2005) Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2:e183PubMedGoogle Scholar
  34. 34.
    Haglund K, Forman J, Krausslich HG et al (2000) Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268:112PubMedGoogle Scholar
  35. 35.
    Haglund K, Leiner I, Kerksiek K et al (2002) Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J Virol 76:7506PubMedGoogle Scholar
  36. 36.
    Harty RN, Paragas J, Sudol M et al (1999) A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol 73:2921PubMedGoogle Scholar
  37. 37.
    Holland J, Spindler K, Horodyski F et al (1982) Rapid evolution of RNA genomes. Science 215:1577PubMedGoogle Scholar
  38. 38.
    Huneycutt BS, Plakhov IV, Shusterman Z et al (1994) Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res 635:81PubMedGoogle Scholar
  39. 39.
    Iverson LE, Rose JK (1981) Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23:477PubMedGoogle Scholar
  40. 40.
    Jacobs BL, Penhoet EE (1982) Assembly of vesicular stomatitis virus: distribution of the glycoprotein on the surface of infected cells. J Virol 44:1047PubMedGoogle Scholar
  41. 41.
    Jayakar HR, Whitt MA (2002) Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol 76:8011PubMedGoogle Scholar
  42. 42.
    Johnson KM, Vogel JE, Peralta PH (1966) Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 15:244PubMedGoogle Scholar
  43. 43.
    Johnson JE, Schnell MJ, Buonocore L et al (1997) Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 71:5060PubMedGoogle Scholar
  44. 44.
    Jones SM, Feldmann H, Stroher U et al (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786PubMedGoogle Scholar
  45. 45.
    Jonkers AH (1967) The epizootiology of the vesicular stomatitis viruses: a reappraisal. Am J Epidemiol 86:286PubMedGoogle Scholar
  46. 46.
    Jonkers AH, Shope RE, Aitken TH et al (1964) Cocal virus, a new agent in Trinidad related to vesicular stomatitis virus, type Indiana. Am J Vet Res 25:236PubMedGoogle Scholar
  47. 47.
    Jonkers AH, Spence L, Aitken TH (1965) Cocal virus epizootiology in Bush Bush Forest and the Nariva Swamp, Trinidad, W.I.: further studies. Am J Vet Res 26:758PubMedGoogle Scholar
  48. 48.
    Justice PA, Sun W, Li Y et al (1995) Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol 69:3156PubMedGoogle Scholar
  49. 49.
    Kahn JS, Schnell MJ, Buonocore L et al (1999) Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254:81PubMedGoogle Scholar
  50. 50.
    Kahn JS, Roberts A, Weibel C et al (2001) Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75:11079PubMedGoogle Scholar
  51. 51.
    Kapadia SU, Rose JK, Lamirande E et al (2005) Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174PubMedGoogle Scholar
  52. 52.
    Klas SD, Robison CS, Whitt MA et al (2002) Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus. Cell Immunol 218:59PubMedGoogle Scholar
  53. 53.
    Klas SD, Lavine CL, Whitt MA et al (2006) IL-12-assisted immunization against listeria monocytogenes using replication-restricted VSV-based vectors. Vaccine 24:1451PubMedGoogle Scholar
  54. 54.
    Kopecky SA, Lyles DS (2003) The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 77:5524PubMedGoogle Scholar
  55. 55.
    Kreis TE, Lodish HF (1986) Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell 46:929PubMedGoogle Scholar
  56. 56.
    Kretzschmar E, Buonocore L, Schnell MJ et al (1997) High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71:5982PubMedGoogle Scholar
  57. 57.
    Lawson ND, Stillman EA, Whitt MA et al (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92:4477PubMedGoogle Scholar
  58. 58.
    Lee BH, Yoshimatsu K, Araki K et al (2006) A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine 24:2928PubMedGoogle Scholar
  59. 59.
    Leppert M, Rittenhouse L, Perrault J et al (1979) Plus and minus strand leader RNAs in negative strand virus-infected cells. Cell 18:735PubMedGoogle Scholar
  60. 60.
    Levenbook IS, Pelleu LJ, Elisberg BL (1987) The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination.J Biol Stand 15:305PubMedGoogle Scholar
  61. 61.
    Lorin C, Mollet L, Delebecque F et al (2004) A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 78:146PubMedGoogle Scholar
  62. 62.
    Lund JM, Alexopoulou L, Sato A et al (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7 (see comment). Proc Natl Acad Sci USA 101:5598PubMedGoogle Scholar
  63. 63.
    Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33:50Google Scholar
  64. 64.
    Maines TR, Lu XH, Erb SM et al (2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79:11788PubMedGoogle Scholar
  65. 65.
    Maximova O, Dragunsky E, Taffs R et al (1996) Monkey neurovirulence test for live mumps vaccine. Biologicals 24:223PubMedGoogle Scholar
  66. 66.
    Metsikko K, Simons K (1986) The budding mechanism of spikeless vesicular stomatitis virus particles. EMBO J 5:1913PubMedGoogle Scholar
  67. 67.
    Miyoshi K, Harter DH, Hsu KC (1971) Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J Neuropathol Exp Neurol 30:266PubMedGoogle Scholar
  68. 68.
    Nathanson N, Horn SD (1992) Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964–1988. Vaccine 10:469PubMedGoogle Scholar
  69. 69.
    Natuk RJ, Cooper D, Guo M et al (2006) Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80:4447PubMedGoogle Scholar
  70. 70.
    Olitsky PK, Cox HR, Syverton JT (1934) Comparative studies on the viruses of vesicular stomatitis and equine encephalomyelitis. J Exp Med 59:159PubMedGoogle Scholar
  71. 71.
    Owens RJ, Rose JK (1993) Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J Virol 67:360PubMedGoogle Scholar
  72. 72.
    Palin A, Chattopadhyay A, Park S et al (2006) An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine (in press). DOI 10.1016/j.vaccine.2006.08.010
  73. 73.
    Pattnaik AK, Hwang L, Li T et al (1997) Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication. J Virol 71:8167PubMedGoogle Scholar
  74. 74.
    Patton JT, Davis NL, Wertz GW (1983) Cell-free synthesis and assembly of vesicular stomatitis virus nucleocapsids. J Virol 45:155PubMedGoogle Scholar
  75. 75.
    Plakhov IV, Arlund EE, Aoki C et al (1995) The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 209:257PubMedGoogle Scholar
  76. 76.
    Pringle CR (1970) Genetic characteristics of conditional lethal mutants of vesicular stomatitis virus induced by 5-fluorouracil, 5-azacytidine, and ethyl methane sulfonate. J Virol 5:559PubMedGoogle Scholar
  77. 77.
    Pringle CR (1982) The genetics of vesiculoviruses. Arch Virol 72:1PubMedGoogle Scholar
  78. 78.
    Ramsburg E, Rose NF, Marx PA et al (2004) Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78:3930PubMedGoogle Scholar
  79. 79.
    Ramsburg E, Publicover J, Buonocore L et al (2005) A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 79:15043PubMedGoogle Scholar
  80. 80.
    Rao TR, Singh KR, Dhanda V et al (1967) Experimental transmission of Chandipura virus by mosquitoes. Indian J Med Res 55:1306PubMedGoogle Scholar
  81. 81.
    Reiss CS, Plakhov IV, Komatsu T (1998) Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci 30:752Google Scholar
  82. 82.
    Reuter JD, Vivas-Gonzalez BE, Gomez D et al (2002) Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76:8900PubMedGoogle Scholar
  83. 83.
    Riedel H, Kondor-Koch C, Garoff H (1984) Cell surface expression of fusogenic vesicular stomatitis virus G protein from cloned cDNA. EMBO J 3:1477PubMedGoogle Scholar
  84. 84.
    Roberts A, Kretzschmar E, Perkins AS et al (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72:4704PubMedGoogle Scholar
  85. 85.
    Roberts A, Buonocore L, Price R et al (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723PubMedGoogle Scholar
  86. 86.
    Robison CS, Whitt MA (2000) The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol 74:2239PubMedGoogle Scholar
  87. 87.
    Rose JK, Whitt MA (2001) Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams and Wilkins, Philadelphia, PA, p 1223Google Scholar
  88. 88.
    Rose NF, Roberts A, Buonocore L et al (2000) Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74:10903PubMedGoogle Scholar
  89. 89.
    Rose NF, Marx PA, Luckay A et al (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539PubMedGoogle Scholar
  90. 90.
    Rowe T, Cho DS, Bright RA et al (2003) Neurological manifestations of avian influenza viruses in mammals. Avian Dis 47:1122PubMedGoogle Scholar
  91. 91.
    Rubin SA, Snoy PJ, Wright KE et al (1999) The mumps virus neurovirulence safety test in rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 180:521PubMedGoogle Scholar
  92. 92.
    Sabin AB, Olitsky PK (1937) Influence of host factors on neuroinvasiveness of vesicular stomatitis virus: I. Effect of age on the invasion of the brain by virus instilled in the nose. J Exp Med 66:15PubMedGoogle Scholar
  93. 93.
    Scheiblauer H, Kendal AP, Rott R (1995) Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species. Arch Virol 140:341PubMedGoogle Scholar
  94. 94.
    Schlereth B, Rose JK, Buonocore L et al (2000) Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74:4652PubMedGoogle Scholar
  95. 95.
    Schnell MJ, Mebatsion T, Conzelmann KK (1994) Infectious rabies viruses from cloned cDNA. EMBO J 13:4195PubMedGoogle Scholar
  96. 96.
    Schnell MJ, Buonocore L, Whitt MA et al (1996) The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70:2318PubMedGoogle Scholar
  97. 97.
    Schnell MJ, Johnson JE, Buonocore L et al (1997) Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90:849PubMedGoogle Scholar
  98. 98.
    Schnell MJ, Buonocore L, Boritz E et al (1998) Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J 17:1289PubMedGoogle Scholar
  99. 99.
    Sharova OK, Rozina EE, Shteinberg LS et al (1979) Morphological characterisitcs of the pathological process in the central nervous system of monkeys infected with variants of measles virus strain L-16. Acta Virol 23:393PubMedGoogle Scholar
  100. 100.
    Shinya K, Hatta M, Yamada S et al (2005) Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol 79:9926PubMedGoogle Scholar
  101. 101.
    tenOever BR, Sharma S, Zou W et al (2004) Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J Virol 78:10636PubMedGoogle Scholar
  102. 102.
    Tesh RB, Johnson KM (1975) Vesicular stomatitis. In: Hubbert WT, McCulloch WF, Schnurrenberger PR (eds) Diseases transmitted from animals to man, 6th edn. C. C. Thomas, Springfield, IL, p 897Google Scholar
  103. 103.
    Tesh RB, Modi GB (1983) Growth and transovarial transmission of Chandipura virus (Rhabdoviridae: Vesiculovirus) in Phlebotomus papatasi. Am J Trop Med Hyg 32:621PubMedGoogle Scholar
  104. 104.
    Tesh RB, Peralta PH, Johnson KM (1970) Ecologic studies of vesicular stomatitis virus. II. Results of experimental infection in Panamanian wild animals. Am J Epidemiol 91:216PubMedGoogle Scholar
  105. 105.
    Tesh RB, Chaniotis BN, Johnson KM (1971) Vesicular stomatitis virus, Indiana serotype: multiplication in and transmission by experimentally infected phlebotomine sandflies (Lutzomyia trapidoi). Am J Epidemiol 93:491PubMedGoogle Scholar
  106. 106.
    Tesh RB, Chaniotis BN, Johnson KM (1972) Vesicular stomatitis virus (Indiana serotype): transovarial transmission by phlebotomine sandflies. Science 175:1477PubMedGoogle Scholar
  107. 107.
    Tesh R, Saidi S, Javadian E et al (1977) Isfahan virus, a new vesiculovirus infecting humans, gerbils, and sandflies in Iran. Am J Trop Med Hyg 26:299PubMedGoogle Scholar
  108. 108.
    Tesh RB, Travassos Da Rosa AP, Travassos Da Rosa JS (1983) Antigenic relationship among rhabdoviruses infecting terrestrial vertebrates. J Gen Virol 64(Pt 1):169PubMedGoogle Scholar
  109. 109.
    Tesh RB, Boshell J, Modi GB et al (1987) Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia. Am J Trop Med Hyg 36:653PubMedGoogle Scholar
  110. 110.
    Travassos da Rosa AP, Tesh RB, Travassos da Rosa JF et al (1984) Carajas and Maraba viruses, two new vesiculoviruses isolated from phlebotomine sand flies in Brazil. Am J Trop Med Hyg 33:999PubMedGoogle Scholar
  111. 111.
    van den Pol AN, Dalton KP, Rose JK (2002) Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 76:1309PubMedGoogle Scholar
  112. 112.
    Villarreal LP, Breindl M, Holland JJ (1976) Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells. Biochemistry 15:1663PubMedGoogle Scholar
  113. 113.
    Wertz GW (1983) Replication of vesicular stomatitis virus defective interfering particle RNA in vitro: transition from synthesis of defective interfering leader RNA to synthesis of full-length defective interfering RNA. J Virol 46:513PubMedGoogle Scholar
  114. 114.
    Wertz GW, Perepelitsa VP, Ball LA (1998) Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95:3501PubMedGoogle Scholar
  115. 115.
    Whelan SP, Wertz GW (1999) Regulation of RNA synthesis by the genomic termini of vesicular stomatitis virus: identification of distinct sequences essential for transcription but not replication. J Virol 73:297PubMedGoogle Scholar
  116. 116.
    Whelan SP, Ball LA, Barr JN et al (1995) Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 92:8388PubMedGoogle Scholar
  117. 117.
    Xing Z, Lichty BD (2006) Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86:211Google Scholar
  118. 118.
    Zagouras P, Rose JK (1993) Dynamic equilibrium between vesicular stomatitis virus glycoprotein monomers and trimers in the Golgi and at the cell surface. J Virol 67:7533PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • David K. Clarke
    • 1
  • David Cooper
    • 1
  • Michael A. Egan
    • 1
  • R. Michael Hendry
    • 1
  • Christopher L. Parks
    • 1
  • Stephen A. Udem
    • 1
    • 2
  1. 1.Department of Vaccines Discovery ResearchWyeth ResearchPearl RiverUSA
  2. 2.International AIDS Vaccine InitiativeNew YorkUSA

Personalised recommendations